OHR Pharmaceutical Inc.

Ohr Pharmaceutical to Announce Second Quarter 2016 Financial Results on May 10

Download PDF

NEW YORK, April 26, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the second quarter ended March 31, 2016 after the market close on Tuesday, May 10, 2016.  The Company will also hold a live investor conference call and webcast at 5:00pm Eastern Time.

Conference Call & Webcast
Tuesday, May 10 at 5:00pm Eastern Time
Domestic: 877-407-0789
International: 201-689-8562
Conference ID: 13636051
Webcast: http://public.viavid.com/index.php?id=119332
   
Replays – Available through May 16, 2016
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 13636051
   

About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead drug candidate, squalamine lactate ophthalmic solution, 0.2% (“Squalamine”, also known as OHR-102), is currently being evaluated in a phase III clinical program for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.

Contact:
Ohr Pharmaceutical Inc.
Investor Relations
888-388-2327
ir@ohrpharmaceutical.com

LifeSci Advisors, LLC
Michael Wood
646-597-6983
mwood@lifesciadvisors.com

Primary Logo

Source: Ohr Pharmaceutical, Inc.